Predict your next investment

Venture Capital
pixvc.com

See what CB Insights has to offer

Investments

25

Portfolio Exits

2

About Pix Vine Capital

Pix Vine Capital is a Singapore-based Investment House providing early-stage venture capital to startups aspiring to commercialize innovative solutions in the areas of Info-Tech, Med-Tech and Eco-Tech.

Pix Vine Capital Headquarter Location

30 Toh Guan Road East Unit 2, Enterprise Hub

608577,

Singapore

+65 65594640

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Pix Vine Capital News

ElastiMed Secures Additional US$1 Million in Funding

Sep 25, 2017

MISGAV, Israel, September 25, 2017 /PRNewswire/ -- ElastiMed Ltd. ("ElastiMed"), announced that it recently raised US$1 million from a strategic investor, existing investors - The Trendlines Group  (SGX: 42T) (OTCQX: TRNLY) and Pix Vine Capital - new private investors, and the Israeli Innovation Authority. This represents the Company's second round of funding, bringing total raises to US$2 million to date. Funds will be used to conduct a clinical study, regulatory filings, and to further expand the Company's current intellectual property. ElastiMed has developed a wearable medical device improving circulation in the legs for the treatment of venous and lymphatic diseases. Based on proprietary technology and utilizing innovative smart materials, ElastiMed's device compresses and massages the legs when stimulated by an electric pulse. The smart sock provides patients with a comfortable, easy-to-wear, highly effective, and affordable treatment option to prevent symptoms such as swelling, blood clots, leg ulcers, and sports injuries. Omer Zelka, Founder & CEO of ElastiMed, commented: "We are thrilled with the support and interest that our existing and new investors have demonstrated. It is indeed a vote of confidence in ElastiMed's future and potential." Todd Dollinger, Chairman and CEO of Trendlines, added: "ElastiMed's huge market is clearly in need of better solutions for chronic edema and DVT. We are proud of ElastiMed's achievements so far and look forward to seeing them enter the marketplace." Patrick De Silva, Chief Investment Partner of Pix Vine Capital, said : "We are excited to continue our support in the potential commercialization of a usable and effective wearable device, to help treat chronic edema and to prevent DVT." About ElastiMed ElastiMed is an Israeli medical device company that develops a wearable medical device to improve circulation in the legs for the treatment of venous and lymphatic diseases. Chronic leg swelling (edema), which is caused by poor circulation, affects more than 7.4 million people in the United States alone[1]. Edema may result from old age, cancer treatments, poor diet or pregnancy. Blood clots, which are formed in the legs (DVT, deep vein thrombosis), affect over 790,000 people in the United States and EU[2]. Applying constant or changing external pressure on the legs has been proven to be a highly effective treatment to improve circulation and reduce swelling[3]. With a more than 60% non-compliance[4] rate for existing treatment options, ElastiMed's device is aimed at improving patient compliance with a comfortable, highly effective clinical treatment. ElastiMed addresses a potential worldwide market of US$3.3 billion. [1] MNT 2017 [2]Aspen 2015 ( http://www.aspenpharma.eu/services/thrombosis-knowledge-center/venous-thromboembolic-events/ ), CDC 2015 ( https://www.cdc.gov/ncbddd/dvt/data.html ) [3]NCBI 2015 ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692571/ )

Pix Vine Capital Investments

25 Investments

Pix Vine Capital has made 25 investments. Their latest investment was in iAgree as part of their Seed VC on January 1, 2018.

CBI Logo

Pix Vine Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/2/2018

Seed VC

iAgree

$1M

Yes

1

11/6/2017

Unattributed VC

SynVaccine

$1.7M

Yes

4

9/25/2017

Seed VC - II

Elastimed

$1M

No

5

6/1/2017

Seed VC

Subscribe to see more

Subscribe to see more

10

8/18/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/2/2018

11/6/2017

9/25/2017

6/1/2017

8/18/2016

Round

Seed VC

Unattributed VC

Seed VC - II

Seed VC

Series A

Company

iAgree

SynVaccine

Elastimed

Subscribe to see more

Subscribe to see more

Amount

$1M

$1.7M

$1M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

5

10

10

Pix Vine Capital Portfolio Exits

2 Portfolio Exits

Pix Vine Capital has 2 portfolio exits. Their latest portfolio exit was Creditseva on October 17, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/17/2018

Acquired

$99M

7

9/28/2017

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/17/2018

9/28/2017

Exit

Acquired

Corporate Majority

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

7

10

Pix Vine Capital Team

1 Team Member

Pix Vine Capital has 1 team member, including current General Partner, Fang Soong Chou.

Name

Work History

Title

Status

Fang Soong Chou

General Partner

Current

Name

Fang Soong Chou

Work History

Title

General Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.